Search Results - shiwen+luo

HOME SEARCH RSS
1 Results Sort By:
Novel Composition for HER2+ Cancer
The Current State of the Art: HER2 (also known as ErbB2), a receptor tyrosine kinase is overexpressed in around 25% of breast cancer cells. It is a known anti-cancer target to the monoclonal antibody, Trastuzumab. Limitation of the Current Art: However, about 20% patients develop resistance to Trastuzumab. Pertuzumab, Lapatinib, and other trastuzumab...
Published: 3/31/2022   |   Inventor(s): Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yanmei Tao, Shiwen Luo
Keywords(s):  
Category(s): Therapeutics
© 2024. All Rights Reserved. Powered by Inteum